More News! British AI scores an ALS drug candidate

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • Arix co-led a €40M ($45M) Series B round for Patrick Baeuerle‘s San Francisco-based company, Harpoon Therapeutics
  • Horizon Discovery has a new gene editing platform for research and therapeutic applications, adding to their already-full arsenal of methods
Oleksii G
  • The EMA struck down XBiotech’s drug with a flat-out rejection, following a negative opinion from CHMP; the Texan biotech remains undeterred
  • BenevolentAI has scored a win with a drug candidate that appears to delay the onset of ALS
  • Hookipa published results demonstrating its TheraT platform’s efficacy at “turning cold tutors hot” to improve their targeting by immuno-oncology therapies.
Brian Lasenby
  • Spider silk is could become a new low-cost lung surfactant as a treatment for respiratory disease and to help pre-term babies breathe, thanks to a group of European researchers

Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.